WS #12351
Abbott posts solid Q2 2026 beat-and-raise, with revenue up 13% YoY to $12.59B, driven by Medical Devices and Cancer Diagnostics; raises FY26 EPS guidance.
Abbott Laboratories Q2 Beat-and-Raise
Abbott posts solid Q2 2026 beat-and-raise, with revenue up 13% YoY to $12.59B, driven by Medical Devices and Cancer Diagnostics; raises FY26 EPS guidance.